OOIR: Observatory of International Research

Papers

(The H4-Index of Annals of Allergy Asthma & Immunology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Atopic dermatitis in the pediatric population	175
New treatments in atopic dermatitis	117
The infectious complications of atopic dermatitis	81
The journey to a respiratory syncytial virus vaccine	75
Asthma and the social determinants of health	68
Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States	65
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma	61
Potential association of mast cells with coronavirus disease 2019	60
Smell loss is a prognostic factor for lower severity of coronavirus disease 2019	54
Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis	52
The COVID-19 pandemic	51
Prevalence and natural history of tree nut allergy	50
New and emerging treatments for inflammatory itch	48
Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019	45
Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters	45
Key steps in vaccine development	45
Hereditary alpha-tryptasemia in 101 patients with mast cell activation–related symptomatology including anaphylaxis	43
Children with reported penicillin allergy	43
The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection	42
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis	42
Secondary immunodeficiencies	41
The impact of psychological stress on mast cells	41
AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis	39
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions	39
Patient satisfaction with telemedicine encounters in an allergy and immunology practice during the coronavirus disease 2019 pandemic	38

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019	36
Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies	35
Making the GRADE in anaphylaxis management	34
Social media and its impact on health care	33
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY	33
Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines	33
Chronic stress and asthma in adolescents	33
Biologics in eosinophilic gastrointestinal diseases	32